Arrowhead Pharmaceuticals Inc. (HDP1)

Profile

https://arrowheadpharma.com

Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference-based medicines to treat diseases driven by genetic abnormalities or excess protein production. The company uses proprietary RNA chemistries and its TRiM platform to selectively silence disease-causing genes across multiple tissues, including liver, lung, muscle, adipose, and central nervous system. Arrowhead’s portfolio spans cardiometabolic and cardiovascular disorders, liver diseases such as alpha-1 antitrypsin deficiency and hepatitis B, pulmonary conditions including idiopathic pulmonary fibrosis and mucus-obstructive lung disease, and rare genetic diseases affecting muscle and complement-mediated pathways. Its first approved product, REDEMPLO (plozasiran), targets familial chylomicronemia syndrome as an adjunct to diet. Beyond wholly owned programs, Arrowhead also collaborates with large pharmaceutical partners to extend the reach of its RNAi therapeutics globally. Founded in 1989 and headquartered in Pasadena, California, with additional R&D and manufacturing facilities in Wisconsin, San Diego, and Ireland, Arrowhead today operates as a specialized player within the biotechnology and healthcare sectors.